Pancreatic cancer family history: hereditary pancreatic cancer risk and surveillance

Short version. Pancreatic cancer carries one of the worst cancer prognoses and a correspondingly high value on early detection for those at elevated risk. Most pancreatic cancer is sporadic, but approximately 5 to 10 percent of cases cluster in families with recognisable hereditary patterns. Familial pancreatic cancer (FPC) is defined as two or more first-degree relatives with pancreatic ductal adenocarcinoma without another identified hereditary syndrome. Known syndromes include HBOC (BRCA2, BRCA1, PALB2), Lynch syndrome, FAMMM (CDKN2A), Peutz-Jeghers (STK11), hereditary pancreatitis (PRSS1 and others), and Li-Fraumeni. High-risk individuals may be candidates for CAPS-guided surveillance. Evagene integrates PancPRO alongside BRCAPRO and MMRpro on a single pedigree canvas, with batch risk screening catching overlapping syndromes automatically.

Pancreatic cancer: epidemiology and the clinical stakes

Pancreatic ductal adenocarcinoma (PDAC) is uncommon relative to breast, colorectal, or lung cancer, but it is one of the most lethal cancers. Lifetime risk in the general population sits around 1 to 2 percent in most high-income countries. Incidence rises steeply with age; most diagnoses are in individuals over 60. Prognosis is poor: five-year survival has historically been in single digits, although contemporary cohort data put it slightly higher for cases diagnosed at early stages where curative surgical resection is possible.

The clinical consequence of this combination — common enough to matter, lethal enough that early detection is of disproportionate value — is that identifying the individuals and families at elevated risk is a high-yield task. Surveillance in unselected populations is not supported by current evidence; surveillance in specifically identified high-risk individuals is supported, and is where CAPS-guided programmes focus.

Familial pancreatic cancer (FPC)

Familial pancreatic cancer is the research-grade definition of a pancreatic cancer kindred: at least two first-degree relatives with pancreatic ductal adenocarcinoma, in the absence of another recognised hereditary cancer syndrome. Kindreds meeting this definition have substantially elevated pancreatic cancer risk over the general population baseline, and the magnitude of the excess risk scales with the number of affected first-degree relatives.

The qualitative pattern is that a single affected first-degree relative confers a modest multiplicative increase in lifetime risk over baseline; two affected first-degree relatives produce a larger increase; three or more produce substantial elevation, particularly when at least one diagnosis was at a young age. Precise figures should be drawn from published cohort data such as the NFPTR (National Familial Pancreas Tumour Registry) and European FPC registries, rather than committed to memory.

Importantly, the FPC phenotype is heterogeneous at the molecular level. Some FPC kindreds are driven by identifiable hereditary cancer syndrome genes (BRCA2 being the most common). Others have no identified pathogenic variant even on contemporary panels, suggesting that a meaningful fraction of the genetic architecture of hereditary pancreatic cancer remains to be characterised. This is one of the reasons PancPRO — a family-history-based model — remains clinically useful alongside gene-panel testing.

Hereditary syndromes that include pancreatic cancer

Several well-recognised hereditary cancer syndromes include pancreatic cancer in their tumour spectrum. The common and clinically actionable contributors are as follows.

• Hereditary breast and ovarian cancer (HBOC). BRCA2 pathogenic variants are the single most frequently identified genetic cause in FPC kindreds. BRCA1 and PALB2 also contribute. Families with pancreatic cancer alongside breast, ovarian, or aggressive prostate cancer should be evaluated for HBOC. See our BRCAPRO calculator and breast cancer family history pages.
• Lynch syndrome. Pancreatic cancer is part of the Lynch tumour spectrum. Kindreds with colorectal or endometrial plus pancreatic cancer should be evaluated for Lynch. See our Lynch syndrome risk calculator and MMRpro calculator.
• Familial atypical multiple mole melanoma (FAMMM). Caused by pathogenic variants in CDKN2A, this syndrome combines melanoma predisposition with elevated pancreatic cancer risk. A family with melanoma plus pancreatic cancer should raise FAMMM in the differential.
• Peutz-Jeghers syndrome. Caused by STK11 pathogenic variants, with mucocutaneous pigmentation and hamartomatous polyps as distinctive features. Peutz-Jeghers carries elevated risk of pancreatic, breast, gastrointestinal, and gynaecological cancers.
• Hereditary pancreatitis. Caused predominantly by PRSS1 pathogenic variants (autosomal dominant), with contributions from SPINK1 and CFTR. Chronic pancreatic inflammation from childhood onwards elevates pancreatic cancer risk over decades, with particularly high risk in long-standing smokers from affected kindreds.
• Li-Fraumeni syndrome. Rare in FPC but occasionally identified, associated with TP53 pathogenic variants.
• ATM. Heterozygous ATM pathogenic variants confer moderately elevated pancreatic cancer risk and are included on contemporary panels.

A contemporary hereditary pancreatic cancer gene panel typically covers BRCA1, BRCA2, PALB2, ATM, CDKN2A, STK11, TP53, the Lynch mismatch repair genes, and the hereditary pancreatitis genes. Even with a comprehensive panel, a substantial fraction of FPC kindreds have no identified pathogenic variant.

Red-flag family history patterns

The features in a family history that should prompt referral and formal hereditary pancreatic cancer evaluation include:

• Two or more first-degree relatives with pancreatic cancer.
• Any first-degree relative with pancreatic cancer combined with breast, ovarian, colorectal, endometrial, or melanoma in the kindred.
• Early-onset pancreatic cancer (under 50) in any relative.
• Ashkenazi Jewish heritage with any pancreatic cancer in the family.
• Personal or family history of hereditary pancreatitis, particularly long-standing chronic pancreatitis from childhood.
• Pedigree features of Peutz-Jeghers (mucocutaneous pigmentation, hamartomatous polyps).
• Pedigree features of FAMMM (multiple atypical melanocytic naevi, melanoma, pancreatic cancer).
• Known pathogenic variant in BRCA1, BRCA2, PALB2, CDKN2A, STK11, ATM, or a Lynch gene in a first-degree relative.

These patterns are triggers for specialist referral. Formal quantitative risk assessment and panel testing follow.

CAPS surveillance: who, when, how

The International Cancer of the Pancreas Screening (CAPS) consortium publishes and updates consensus recommendations for pancreatic cancer surveillance in defined high-risk groups. The groups for whom surveillance is considered include FPC kindred members meeting defined criteria, carriers of specific hereditary cancer syndrome genes with or without a family history of pancreatic cancer, individuals with hereditary pancreatitis, and individuals with Peutz-Jeghers syndrome.

The typical surveillance programme is annual imaging with endoscopic ultrasound (EUS) or MRI/MRCP of the pancreas, starting at an age determined by the specific genetic background and family history. For example, surveillance may start earlier in Peutz-Jeghers or hereditary pancreatitis than in FPC kindreds without an identified gene. The specific age cut-offs and surveillance intervals are set by the prevailing CAPS consensus and local commissioning — services should follow current published guidance rather than committed figures.

Surveillance carries real costs. It is resource-intensive, requires specific endoscopic and radiological expertise, and can generate findings of uncertain significance (small cystic lesions, for example) that lead to invasive follow-up. CAPS and equivalent guidance emphasise that surveillance should be delivered within a multidisciplinary high-risk pancreatic clinic, ideally linked to a registry programme, with clear informed consent about the uncertainties.

PancPRO contributes to surveillance decisions by quantifying family-history-based risk in families without an identified gene, or by complementing gene-panel results where one is found. See our PancPRO calculator guide for the underlying methodology.

Modifiable risk factors

Hereditary pancreatic cancer risk sits on top of an environmental baseline that is partially modifiable. Key modifiable factors are:

• Smoking. The single most consequential modifiable risk factor for pancreatic cancer. It interacts multiplicatively with inherited risk, and in hereditary pancreatitis kindreds in particular, smoking cessation is of disproportionate value.
• Heavy alcohol use. Associated with chronic pancreatitis which itself elevates pancreatic cancer risk.
• Obesity and long-standing diabetes. Both are associated with modestly elevated risk.
• Chronic pancreatitis of any cause, not only hereditary.

Risk counselling in high-risk individuals should address these factors alongside genetic counselling and surveillance planning.

From family history to clinical action: the workflow

A typical workflow for a hereditary pancreatic cancer evaluation proceeds in stages. First, construct a three-generation pedigree on both parental lineages, annotated with every cancer (pancreatic, breast, ovarian, colorectal, endometrial, melanoma, stomach, prostate, and others), ages at diagnosis, vital status, and ethnicity. Capture personal and family history of chronic pancreatitis explicitly because the hereditary pancreatitis differential can be missed otherwise.

Second, identify the candidate syndromes. Pancreatic plus breast or ovarian suggests HBOC. Pancreatic plus colorectal or endometrial suggests Lynch. Pancreatic plus melanoma suggests FAMMM. Pancreatic with mucocutaneous pigmentation or childhood polyps suggests Peutz-Jeghers. Pancreatic with childhood-onset recurrent pancreatitis suggests hereditary pancreatitis.

Third, run the appropriate quantitative models. BRCAPRO for HBOC, MMRpro for Lynch, PancPRO for family-history-weighted pancreatic susceptibility. Ideally these run on the same pedigree in a single operation.

Fourth, proceed with appropriate gene-panel testing for identified candidates. Where a pathogenic variant is found, cascade testing of first-degree relatives follows.

Fifth, for individuals identified as high-risk by PancPRO or by a confirmed gene finding, discuss surveillance within a multidisciplinary high-risk pancreatic clinic per CAPS guidance.

How Evagene integrates pancreatic cancer risk workflows

Evagene is designed for exactly this multi-syndrome evaluation. The pedigree is drawn once on a browser-based canvas using standard clinical notation, with disease annotation against ICD-10 and OMIM codes across a 200-plus disease catalogue that includes pancreatic adenocarcinoma, the various melanoma subtypes, the Lynch spectrum, hereditary pancreatitis, Peutz-Jeghers and FAMMM in its own right, and more.

From the same pedigree, batch risk screening runs BRCAPRO (for HBOC / BRCA2 pancreatic contribution), MMRpro (for Lynch pancreatic contribution), PancPRO (for family-history-weighted pancreatic susceptibility), and Mendelian inheritance analyses across the full disease catalogue — all in one operation, with configurable thresholds that flag conditions for clinician attention. A pedigree where the clinician's initial suspicion was pancreatic but which actually fits an FAMMM pattern, or a Peutz-Jeghers pattern, has that suspicion raised automatically rather than depending on the clinician remembering to consider it.

The BayesMendel models (BRCAPRO, MMRpro, PancPRO) run in an R sidecar process that invokes the validated upstream R package, so the underlying calculations are the same as those in peer-reviewed research and clinical guidelines. Mendelian inheritance calculators cover autosomal dominant, autosomal recessive, and X-linked recessive conditions — useful when the differential widens beyond the cancer syndromes (hereditary pancreatitis's autosomal dominant inheritance, for example).

AI interpretation with bring-your-own-key large language models (Anthropic Claude, OpenAI GPT) drafts structured clinical summaries combining pedigree findings with risk results, framing the candidate syndromes, suggesting panels, and surfacing data gaps. Traffic goes directly to the LLM provider you contract with; Evagene's role is orchestration and prompt templating, not intermediating clinical text.

For programmatic use, all of the above is available through the REST API and MCP server, supporting EHR integrations, research pipelines, and AI agents. Documentation is at evagene.net/help. Evagene is browser-based, zero install, and free during Alpha via the waiting list.

Frequently asked questions

Related reading

• PancPRO calculator
• BRCAPRO calculator
• MMRpro calculator
• Lynch syndrome risk calculator
• Breast cancer family history calculator
• Ovarian cancer family history calculator
• Hereditary cancer risk assessment
• Pedigree drawing software
• Clinical genetics pedigree tool
• Mendelian inheritance calculator
• GEDCOM pedigree software
• Phenotips vs Evagene comparison